GLP-1RAs and Pancreatic Cancer Unrelated Among Type 2 Diabetes Patients
A study published in JAMA Network Open suggested that there is no link between the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and pancreatic cancer risk among adults with type 2 diabetes over a period of up to 7 years. The researchers conducted a cohort study on over 500,000 participants and found no significant increase…